A recently identified mechanism for oligomeric Aβ-induced glutamate release from astrocytes involves intracellular Ca 2 + elevation, potentially by Ca 2 + -dependent vesicular release. Evidence suggests that levetiracetam (LEV; Keppra), an antiepileptic drug, can improve cognitive performance in both humans with mild cognitive impairment and animal models of Alzheimer disease. Because LEV acts by modulating neurotransmitter release from neurons by interaction with synaptic vesicles, we tested the effect of LEV on Aβ-induced astrocytic release of glutamate. We used a fluorescence resonance energy transfer-based glutamate sensor (termed SuperGluSnFR), whose structure is based on the ligand-binding site of glutamate receptors, to monitor glutamate release from primary cultures of human astrocytes exposed to oligomeric amyloid-β peptide 1-42 (Aβ 42 ). We found that LEV (10 µM) inhibited oligomeric Aβ-induced astrocytic glutamate release. In addition, we show that this Aβ-induced glutamate release from astrocytes is sensitive to tetanus neurotoxin, an inhibitor of the vesicle release machinery. Taken together, our evidence suggests that LEV inhibits Aβinduced vesicular glutamate release from astrocytes and thus may underlie, at least in part, the ability of LEV to reduce hyperexcitability in Alzheimer disease. NeuroReport 27:705-709
Introduction
Levetiracetam (LEV) is an antiepileptic drug with known procognitive properties [1] . Preclinical experiments have shown that LEV improves memory retrieval [2] and restores cognitive function in mouse models of Alzheimer's disease (AD) [3, 4] . In humans, clinical studies suggest that LEV, at doses as low as 250 mg/day, can improve cognitive performance in patients with amnestic mild cognitive impairment [5] , a condition that often precedes the onset of AD. LEV procognitive effects likely result from its ability to reduce abnormal neuronal hyperactivity in regions of the brain involved in learning and memory [5] . In the brain, LEV reportedly interacts with synaptic vesicles in neurons [6] to modulate Ca 2 +dependent vesicular release of neurotransmitter such as glutamate. Importantly, glutamate levels are also tightly controlled by astrocytes [7] , and impaired astrocytic metabolism and clearance of extracellular glutamate have been linked to the pathophysiology of AD [8, 9] . Thus, we examined the effect of LEV on astrocytic handling of glutamate in the presence of oligomeric amyloid-β peptide 1-42 (Aβ 42 ), which is believed to be a key mediator of AD [10] . It was recently shown that picomolar to nanomolar oligomeric Aβ 42 can trigger Ca 2 + -dependent glutamate release from astrocytes, contributing toward increased extracellular glutamate in the brain, with consequent overactivation of extrasynaptic N-methyl-Daspartate receptors and synaptic loss [11] ; other amino acids were not released by oligomeric Aβ 42 in this paradigm. In the present study, we show that therapeutically relevant concentrations of LEV can significantly reduce this oligomeric Aβ-induced astrocytic release of glutamate, most likely by interaction with the vesicular release machinery.
Materials and methods

Cell cultures
To utilize the glutamate-sensor SuperGluSnFR in astrocyte cultures, the probe was engineered in HEK 293T 'interrogator' cells' as described previously [11] . For this purpose, HEK 293T cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin, and streptomycin in a humidified 5% CO 2 /balance air atmosphere incubator that was kept at 37°C. Once confluent, cells were enzymatically dissociated with trypsin-EDTA, seeded at 1 × 10 5 cells/well, cotransfected with SuperGluSnFR and neuroligin plasmids (1 µg each/well) using 1 µl Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA), and used for glutamate fluorescence resonance energy transfer (FRET) assays within 24-48 h of transfection. Normal human astrocytes (NHA; Lonza, Basel, Switzerland) were cultured in astrocyte growth medium (AGM; Lonza) in a humidified 5%CO 2 /air atmosphere incubator at 37°C [12] .
Glutamate FRET imaging
FRET microscopy was performed using the SuperGluSnFR probe to monitor glutamate release from pure human astrocyte cultures. To detect the release of glutamate, astrocytes were plated on top of HEK-293 cells expressing the SuperGluSnFR probe and neuroligin. In this assay, neuroligin is used to bring the HEKinterrogator cell into close apposition with the overlying astrocytes [11] . Under these conditions, changes in extracellular glutamate can be detected within a wide dynamic range of glutamate concentrations (300 nM to 100 µM) [13] . Experiments were conducted on an inverted microscope (Axiovert 100 M; Zeiss, Oberkochen, Germany) equipped for epifluorescence microscopy. Coverslips were placed on the stage and light was delivered to the sample through a × 63 oil immersion objective (1.4 numerical aperture). Cells were superfused continuously at room temperature (22°C) with an extracellular solution (in mM): NaCl 146, KCl 2.5, NaOH 4, CaCl 2 1, D-glucose 20, sucrose 20, and HEPES 10, adjusted to pH 7.4. Drugs and reagents were added manually using a micropipette. Cells were epi-illuminated alternately at 434 and 514 nm, and emitted light was collected at 527 and 476 nm for yellow fluorescent protein (YFP) and cyan fluorescent protein (CFP), respectively. In a typical experiment, 3-7 regions of interest (ROI) were imaged, each containing an HEK-FRET sensor cell and one or more astrocytes. Peak CFP/ YFP ratio was divided by baseline CFP/YFP ratio and plotted after baseline normalization to a value of 1. Images were obtained every second following a 400 ms stimulus and processed using SlideBook software (Intelligent Imaging Innovations, Santa Monica, California, USA). A 2 × 2 binning method was used to improve the signal-tonoise ratio and minimize photobleaching.
Oligomeric Aβ preparation
Oligomeric Aβ was prepared as described previously [11] . Synthetic human Aβ 42 peptide (GenicBio Ltd, Shanghai, China, or Anaspec Inc., Freemont, California, USA) was suspended to an initial concentration of 1 mM in hexafluoroisopropanol, incubated for 2 h at room temperature, and solvent evaporated in a SpeedVac (Savant, Thermo Fisher Scientific, Waltham, Massachusetts, USA). Peptide was resuspended in dry dimethyl sulfoxide as monomers and frozen at − 80°C until use. For oligomerization, Aβ 42 peptide was incubated at 4°C for at least 24 h and sonicated before use. In the present study and in previous studies, the oligomeric, but not the monomeric, form of Aβ 42 was found to exert the effects studied here [11] . The total concentration of Aβ 42 was monitored by enzymelinked immunosorbent assay after centrifugation at 11 000 g for 2 min. To characterize the degree of oligomerization of the preparations, western blot and light scattering analyses were carried out before and after centrifugation as described previously [11] . For experiments, both monomeric and oligomeric synthetic Aβ 42 preparations were diluted in physiological buffer.
Statistical analysis
Results are reported from at least five independent observations and expressed as mean SEM. Statistical analysis and representation were carried out using GraphPad Prism 6 (GraphPad Software Inc., San Diego, California, USA).
Comparison of values was made using a two-tailed Student's t-test for statistical significance. A P-value of less than 0.05 was considered to be statistically significant.
Results
Levetiracetam inhibits glutamate release from human astrocytes
We and others have previously shown that preparations of Aβ 42 oligomers can trigger glutamate release from astrocytes; importantly, however, monomeric Aβ 42 did not result in glutamate release [11] . Specifically, nanomolar concentrations of synthetic Aβ 42 oligomers or picomolar concentrations of natural Aβ 42 oligomers prepared from human AD brain were shown to trigger glutamate release [11] . In the present study, to test the effect of LEV on oligomeric Aβ-induced astrocytic glutamate release, we incubated primary human astrocytes in LEV (10 µM) for 30 min and measured glutamate release using the SuperGluSnFR, a FRET-based glutamate sensor probe [13] . Before exposure to synthetic Aβ oligomers, probe sensitivity and maximal level of response to glutamate were assessed by bath application of saturating concentrations of glutamate (100-300 µM) as described previously [13] . As shown in Fig. 1a , the change in FRET fluorescence intensity, reflecting glutamate concentration, was significantly increased after bath application of 100 µM glutamate (as a control) or 250 nM oligomeric Aβ 42 . In contrast, preincubation in LEV (10 µM) significantly inhibited oligomeric Aβ 42 -induced glutamate release, but not the response to control glutamate application (Fig. 1b) . These responses are quantified in Fig. 1c .
Oligomeric Aβ induces vesicular glutamate release from astrocytes
To determine whether Aβ-induced astrocytic glutamate release is indeed dependent on vesicular release, we applied oligomeric human Aβ 42 to human astrocytes that had been preincubated in a tetanus neurotoxin lightchain (TeNT-LC) peptide for 24 h versus control conditions (Fig. 2b and c) [14] . TeNT-LC inhibited Aβ-induced astrocytic glutamate release. Taken together, our data suggest that oligomerized Aβ triggers the vesicular release of glutamate from human astrocytes. Moreover, this conclusion is consistent with previous evidence that astrocytic release of glutamate can be mediated by Ca 2 + -dependent vesicular exocytosis [15] .
Discussion
Recent evidence has suggested in rodent brain, studied by microdialysis, that LEV can reduce extracellular levels of the excitatory neurotransmitter glutamate in vivo [16] .
To account for this effect, it was previously assumed that LEV prevented glutamate release from the synaptic endings of neurons. Unexpectedly, here, we found that LEV also inhibits the release of glutamate from human astrocytes. Importantly, our group and others previously showed that oligomeric Aβ can induce astrocytic glutamate release by α7 nicotinic receptors in a calciumdependent manner to contribute toward synaptic damage [11, 17] . Here, we report that this Aβ-induced glutamate release is vesicular in nature because it can be blocked by TeNT-LC. Moreover, LEV can abrogate the release of glutamate. This new finding may account, at least in part, for the therapeutic benefit of LEV that has been observed in mouse models of AD [3, 4] .
Mechanistically, it has been posited that LEV and similar drugs such as brivaracetam bind to the synaptic vesiclerelated protein SV2A in neurons, accounting for their ability to reduce excitation, possibly by inhibition of glutamate release from presynaptic terminals. One caveat with this reasoning is the fact that SV2A is expressed in both excitatory glutamatergic and inhibitory GABAergic neurons [18, 19] . Inhibition of SV2A activity might therefore be expected to affect both glutamatergic and GABAergic synaptic transmission. Moreover, deletion of the SV2A gene has been shown to exert opposite effects on glutamatergic and GABAergic neurotransmission, with decreased GABAergic synaptic currents [20] , but increased glutamatergic transmission [21] . Thus, LEV might be acting as a positive allosteric modulator of SV2A, resulting in decreased glutamate release. In addition, LEV appears to lack a significant effect on other neuronal parameters that might influence glutamate release, including passive and active neuronal membrane properties [22] , neuronal fast or persistent Na + currents [23, 24] , neuronal low voltage-activated calcium currents [23, 24] , and evoked excitatory postsynaptic potentials [24] .
Against this background, and with the recent report that the molecular target of LEV, SV2A, is present in acutely isolated cortical astrocytes [25] , our new findings suggest that LEV can also reduce excitation emanating from gliotransmission, that is, vesicular release of glutamate from astrocytes (Fig. 3) . This opens up an entirely new avenue for drug action and future drug development, taking advantage of an alternative mechanism of action based on LEV-mediated inhibition of glutamate release from astrocytes rather than only from neurons. Recently, the contribution of astrocytes has come to the forefront of neuroscience research not only in mediating normal neuronal-glial communication in the brain but also in contributing toward neurological diseases, including AD [11] . In this light, it is likely that glial release of transmitters such as glutamate, as studied here, may well play a role in both physiological and pathophysiological processes mediated by astrocytes in the central nervous system. Moreover, LEV and related drugs may prove to be a useful tool as well as therapeutic to modulate the astrocytic release mechanism.
Conclusion
The antiepileptic drug LEV and similar drugs such as brivaracetam [26] have been reported to ameliorate cognitive deficits in animal models of AD or to improve performance in human patients with mild cognitive impairment. LEV reduces potentially harmful hyperexcitability in the brain by inhibiting vesicular release of neurotransmitters from neurons. However, to date, there has been no evidence that LEV can target neurotransmitter release from glial cells, which also use vesicular exocytosis. Here, we show that LEV inhibits glutamate release from astrocytes exposed to toxic levels of oligomeric Aβ 42 , believed to be a key mediator of AD. Our evidence suggests that the positive effects of LEV and similar drugs in transgenic mouse models of AD may result from the drug's ability to target both dysfunctional neurotransmission and gliotransmission.
